Sodium-dependent glucose transporter 2 inhibitors effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure

Figure 1 Mean change in high-sensitivity C-reactive protein concerning treatment group and baseline high sensitivity C-reactive protein level. DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT2i: hsCRP: High-sensitivity C-reactive protein; Sodium-dependent glucose transporters inhibitors.

Figure 2 Mean change in systolic blood pressure concerning treatment group and its baseline level. DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT2i: Sodium-dependent glucose transporters inhibitors.

Figure 3 Mean change in diastolic blood pressure concerning treatment group and its baseline level. DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT2i: Sodium-dependent glucose transporters inhibitors.

Figure 4 Mean change in global longitudinal strain concerning treatment group and baseline global longitudinal strain level. GLS: Global longitudinal strain; DPP-4i: Dipeptidyl peptidase-4 inhibitors; SGLT2i: Sodium-dependent glucose transporters inhibitors.